Literature DB >> 29440136

Problems in anticoagulation of a patient with antibiotic treatment for endocarditis: interaction of rifampicin and vitamin K antagonists.

Lars Mizera1, Tobias Geisler1, Klaus Mörike2, Meinrad Gawaz1, Martin Steeg1.   

Abstract

The cytochrome P450 is a superfamily of isoenzymes that are responsible for the metabolism of many drugs. Significant changes in pharmacokinetics and drug interactions may be due to induction of hepatic cytochrome P450 enzymes. Rifampicin is a common inducer of CYP3A4. We report a case of a 57-year-old woman who was suspected for endocarditis and therefore treated with rifampicin. Due to previous mechanical aortic valve replacement, she also received phenprocoumon for anticoagulation. Although continuing anticoagulant therapy, antibiotic coadministration led to normal international normalised ratio (INR) level. Fifteen days after the treatment with rifampicin ended, INR returned to therapeutic level. © BMJ Publishing Group Ltd (unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  drug interactions; valvar diseases

Mesh:

Substances:

Year:  2018        PMID: 29440136      PMCID: PMC5836613          DOI: 10.1136/bcr-2016-215155

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  16 in total

1.  Dabigatran versus warfarin in patients with mechanical heart valves.

Authors:  John W Eikelboom; Stuart J Connolly; Martina Brueckmann; Christopher B Granger; Arie P Kappetein; Michael J Mack; Jon Blatchford; Kevin Devenny; Jeffrey Friedman; Kelly Guiver; Ruth Harper; Yasser Khder; Maximilian T Lobmeyer; Hugo Maas; Jens-Uwe Voigt; Maarten L Simoons; Frans Van de Werf
Journal:  N Engl J Med       Date:  2013-08-31       Impact factor: 91.245

2.  1173C>T polymorphism in VKORC1 modulates the required warfarin dose.

Authors:  K Kosaki; C Yamaghishi; R Sato; H Semejima; H Fuijita; K Tamura; K Maeyama; H Yamagishi; A Sugaya; H Dodo; Y Tanigawara; T Takahashi
Journal:  Pediatr Cardiol       Date:  2006 Nov-Dec       Impact factor: 1.655

3.  Delayed de-induction of CYP2C9 compared to CYP3A after discontinuation of rifampicin: Report of two cases
.

Authors:  Soichi Shibata; Harumi Takahashi; Akiyasu Baba; Kei Takeshita; Koichiro Atsuda; Hajime Matsubara; Hirotoshi Echizen
Journal:  Int J Clin Pharmacol Ther       Date:  2017-05       Impact factor: 1.366

4.  Guidelines on the management of valvular heart disease (version 2012).

Authors:  Alec Vahanian; Ottavio Alfieri; Felicita Andreotti; Manuel J Antunes; Gonzalo Barón-Esquivias; Helmut Baumgartner; Michael Andrew Borger; Thierry P Carrel; Michele De Bonis; Arturo Evangelista; Volkmar Falk; Bernard Iung; Patrizio Lancellotti; Luc Pierard; Susanna Price; Hans-Joachim Schäfers; Gerhard Schuler; Janina Stepinska; Karl Swedberg; Johanna Takkenberg; Ulrich Otto Von Oppell; Stephan Windecker; Jose Luis Zamorano; Marian Zembala
Journal:  Eur Heart J       Date:  2012-08-24       Impact factor: 29.983

5.  A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin.

Authors:  Giovanna D'Andrea; Rosa Lucia D'Ambrosio; Pasquale Di Perna; Massimiliano Chetta; Rosa Santacroce; Vincenzo Brancaccio; Elvira Grandone; Maurizio Margaglione
Journal:  Blood       Date:  2004-09-09       Impact factor: 22.113

Review 6.  Pharmacogenetics of oral anticoagulants: a basis for dose individualization.

Authors:  Simone Stehle; Julia Kirchheiner; Andreas Lazar; Uwe Fuhr
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

7.  Guidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009): the Task Force on the Prevention, Diagnosis, and Treatment of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and the International Society of Chemotherapy (ISC) for Infection and Cancer.

Authors:  Gilbert Habib; Bruno Hoen; Pilar Tornos; Franck Thuny; Bernard Prendergast; Isidre Vilacosta; Philippe Moreillon; Manuel de Jesus Antunes; Ulf Thilen; John Lekakis; Maria Lengyel; Ludwig Müller; Christoph K Naber; Petros Nihoyannopoulos; Anton Moritz; Jose Luis Zamorano
Journal:  Eur Heart J       Date:  2009-08-27       Impact factor: 29.983

8.  Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2.

Authors:  Simone Rost; Andreas Fregin; Vytautas Ivaskevicius; Ernst Conzelmann; Konstanze Hörtnagel; Hans-Joachim Pelz; Knut Lappegard; Erhard Seifried; Inge Scharrer; Edward G D Tuddenham; Clemens R Müller; Tim M Strom; Johannes Oldenburg
Journal:  Nature       Date:  2004-02-05       Impact factor: 49.962

9.  Physiologically based pharmacokinetic modeling of CYP3A4 induction by rifampicin in human: influence of time between substrate and inducer administration.

Authors:  Guillaume Baneyx; Neil Parrott; Christophe Meille; Athanassios Iliadis; Thierry Lavé
Journal:  Eur J Pharm Sci       Date:  2014-02-12       Impact factor: 4.384

10.  Chronological effects of rifampicin discontinuation on cytochrome P450 activity in healthy Japanese volunteers, using the cocktail method.

Authors:  N Inui; T Akamatsu; S Uchida; S Tanaka; N Namiki; M Karayama; K Chida; H Watanabe
Journal:  Clin Pharmacol Ther       Date:  2013-08-23       Impact factor: 6.875

View more
  2 in total

1.  Deep vein thrombosis of the left arm revealing an asymptomatic pulmonary tuberculosis.

Authors:  Anis Hariz; Mouna Guermazi; Mohamed Salah Hamdi; Imen Boukhris
Journal:  BMJ Case Rep       Date:  2019-06-02

2.  Two Strategies for the Dosage of Acenocoumarol Co-Administered with Rifampicin in Staphylococcal Prosthetic Valve Endocarditis.

Authors:  Marcin Wełnicki; Małgorzata Buksińska-Lisik; Artur Mamcarz
Journal:  Antibiotics (Basel)       Date:  2021-01-03
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.